Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in Working CapitalChange in Working CapitalExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Cash from Investing Activities (2019 - 2023)

Innate Pharma posted quarterly Cash from Investing Activities of -$267875.4 for Q2 2023, up 36.45% year-on-year from -$196324.5 in Q2 2022, and up 36.45% on a QoQ basis from -$421487.4 in Q2 2022.

Innate Pharma (IPHA) has 5 years of Cash from Investing Activities data on file, last reported at -$267875.4 in Q2 2023.

  • For the quarter ending Q2 2023, Cash from Investing Activities rose 36.45% year-over-year to -$267875.4; the trailing twelve-month figure through Jun 2023 stood at -$2.0 million (up 88.5% YoY), and the FY2025 full-year result was $8.5 million, down 13.69% from the prior year.
  • Cash from Investing Activities for Q2 2023 stood at -$267875.4, up from -$421487.4 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$267875.4 in Q2 2023 and bottomed at -$69.4 million in Q2 2019.
  • The 5-year median for Cash from Investing Activities is -$7.2 million (2020), against an average of -$21.2 million.
  • The widest annual swing landed in 2021, when Cash from Investing Activities surged 97.77%; it then tumbled 41.7% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at -$68.8 million in 2019, then surged by 76.82% to -$15.9 million in 2020, then surged by 93.42% to -$1.0 million in 2021, then soared by 59.82% to -$421487.4 in 2022, then jumped by 36.45% to -$267875.4 in 2023.
  • The last three Cash from Investing Activities figures came in at -$267875.4 (Q2 2023), -$421487.4 (Q2 2022), and -$1.0 million (Q4 2021), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -2.89 Mn
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn 638.50 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn -431.90 Mn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn -428.90 Mn
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn -25.54 Mn
10 Innate Pharma 199.64 Mn 199.64 Mn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2023 -267,875.40
Jun 30, 2023 -267,875.40
Jun 30, 2022 -421,487.39
Jun 30, 2022 -421,487.39
Dec 31, 2021 -1.05 Mn
Dec 31, 2021 -1.05 Mn
Jun 30, 2021 -297,455.04
Jun 30, 2021 -297,455.04
Dec 31, 2020 -15.94 Mn
Dec 31, 2020 -15.94 Mn
Jun 30, 2020 -13.34 Mn
Jun 30, 2020 -13.34 Mn
Dec 31, 2019 -68.76 Mn
Dec 31, 2019 -68.76 Mn
Jun 30, 2019 -69.44 Mn
Jun 30, 2019 -69.44 Mn